Literature DB >> 3330386

Race, zygosity, and mortality among twins: interaction of myth and method.

C E Boklage1.   

Abstract

For epidemiological purposes, it is customary to assume that same-sex (SS) dizygotic (DZ) twin pairs are approximately equal in number to unlike-sex (OS)-DZs, the remainder of the SS pairs being monozygotic (MZ). It is also customary to consider OS-DZs to be epidemiologically representative of all DZs, which can only mean that difference in frequency of any trait between OS and SS twins is due to the MZ fraction of the SS twins. Since this is assumed as a premise, there is little value in its usual appearance as the result. The basic tenet of twin biology, that most twin excess anomalies are due to MZs, is a myth self-perpetuated by a methodological tautology, and is false, at least for mortality. In a consecutively ascertained and prospectively studied sample of 616 twin pairs, over 80% diagnosed for zygosity, it can be shown that the standard assumption mentioned above have given impossible answers. The most probable possible answer is that mortality does not differ greatly with zygosity overall, but that SSDZ mortality is much higher than that of OS twins, and probably even higher than that of MZs. Race differences in the probable answers further suggest that standard assumptions of the Weinberg method may have consistently provided false explanations for race differences in the OS fraction of twin pairs.

Entities:  

Mesh:

Year:  1987        PMID: 3330386     DOI: 10.1017/s0001566000006036

Source DB:  PubMed          Journal:  Acta Genet Med Gemellol (Roma)        ISSN: 0001-5660


  2 in total

Review 1.  Traces of embryogenesis are the same in monozygotic and dizygotic twins: not compatible with double ovulation.

Authors:  Charles E Boklage
Journal:  Hum Reprod       Date:  2009-02-27       Impact factor: 6.918

2.  Cortisol advantage of neighbouring the opposite sex in utero.

Authors:  R Fishman; Y Vortman; U Shanas; L Koren
Journal:  R Soc Open Sci       Date:  2018-09-05       Impact factor: 2.963

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.